[Human cytomegalovirus infection].
Tanaka-Taya
Keiko
K
Infectious Disease Surveillance Center, National Institute of Infectious Diseases.
D000998:Antiviral Agents / Q000627:therapeutic use; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000175:diagnosis / Q000276:immunology / Q000628:therapy / Q000821:virology; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications; D006801:Humans; D016219:Immunotherapy, Adoptive; D009894:Opportunistic Infections / Q000150:complications; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D014180:Transplantation / Q000009:adverse effects; D014765:Viral Vaccines; D005719:gamma-Globulins / Q000627:therapeutic use
D000998:Antiviral Agents; D018894:Reverse Transcriptase Inhibitors; D014765:Viral Vaccines; D005719:gamma-Globulins; D017245:Foscarnet; D015774:Ganciclovir